Investors opposed Visiopharm's plan for an initial public offering in Sweden - now the company is considering becoming listed in Denmark
The dream of an initial public offering in Denmark is still alive at picture diagnostics firm Visiopharm, which was a hair's breadth away from entering the stock exchange in Stockholm in 2018. But new investors gave the company 100 million good reasons to choose Copenhagen - and their preferences haven't changed.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT
So close, and yet so far.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
